Evaluation Harnessing the Utility of Selective Sphingosine 1-Phosphate Receptor Modulators to Optimize Patient Care in IBD Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). To what extent are you able to better achieve each of the following learning objectives? Describe the mechanisms of action of S1PR modulators and the implications for IBD management 5 4 3 2 1 Evaluate the most current clinical data associated with available and emerging S1PR modulators 5 4 3 2 1 Implement personalized treatment plans for patients with IBD by incorporating appropriate predictive biomarker analysis, improving patient communication, and addressing barriers to adherence 5 4 3 2 1 Please rate the faculty on the following: Raymond K. Cross, Jr., MD, MS, AGAF, FACG : Knowledge, expertise, and teaching ability 5 4 3 2 1 Please rate the following components relating to this activity: Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Audience-participation portions (eg., Q&A, polling, pre/post-testing) 5 4 3 2 1 Resources and/or other materials supporting the activity 5 4 3 2 1 Overall 5 4 3 2 1 Therapeutic recommendations presented in this activity did not encourage inappropriate or excessive use of products/devices. Agree Disagree How many patients with IBD do you see during a typical week? 0 patients 1-10 patients 11-20 patients 21-30 patients More than 30 patients Do you feel like there were any new data presented? Yes, please specify: No Did you learn anything new? Yes, please specify: No Did you gain confidence on the new information? Yes, why? No, why? Did this program include opportunities to learn as a part of a healthcare team? Yes, please specify: No S1PR modulators indirectly antagonize the receptor’s function leading to which of the following? Decreased peripheral circulation of cells involved in immune surveillance (eg, monocytes and NK cells) Increased peripheral circulation of cells involved in immune surveillance (eg, monocytes and NK cells) Sequestration of lymphocytes in the lymph nodes, reducing circulating lymphocyte counts Sequestration of lymphocytes within inflamed tissue, reducing circulating lymphocyte counts In a recent open-label extension study, approximately half of the patients with moderate to severe UC who did not meet clinical response after 10 weeks of ozanimod therapy benefited from an additional ______ weeks of ozanimod therapy. 2-5 5-10 10-15 15-20 Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No How confident are you in your ability to incorporate emerging therapies into IBD management strategies to address suboptimal outcomes in appropriate patients? Very confident Confident Somewhat confident Not very confident Not at all confident What challenges or barriers outside of your control may prevent you from changing your practice? Adverse effects of available treatments Affordability/cost Institutional policy Insurance/formulary Lack of patient education/engagement Limited resources/time Need more information on optimal management strategies Outdated or unclear guidelines Patient adherence Other: How might future activities help you address those barriers? 255 characters max The information presented in this activity did not serve to advance a proprietary interest of any commercial entity. Agree Disagree Based on my participation in this activity, I anticipate I will more often: (select all that apply) Carefully consider patient perceptions of IBD disease severity and impact of disease Assess patient preferences regarding treatment, including barriers to adherence Incorporate patient characteristics, disease severity, comorbidities, and response to previous therapies into personalized management strategies Remain apprised of the clinical data associated with newer and emerging therapies for UC and CD Incorporate the use of S1PR modulators as induction therapy in IBD where appropriate Incorporate the use of S1PR modulators as maintenance therapy in IBD where appropriate Switch a patient to a biosimilar when clinically appropriate Other (please specify): Previous